Stockreport

NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc. [Yahoo! Finance]

NLS Pharmaceutics Ltd. - Ordinary Shares  (NLSP) 
PDF Exclusive option agreement accesses global rights to multiple highly selective Orexin-1 / Orexin-2 receptor agonists, unique compounds designed for specificity, acting [Read more]